Association of β-Blocker Therapy at Discharge with Clinical Outcomes after Acute Coronary Syndrome in Patients without Heart Failure.
Yan ChenXiao-Fang TangRun-Lin GaoYue-Jin YangBo XuJin-Qing YuanPublished in: Cardiovascular therapeutics (2020)
We present that β-blocker significantly lowers the rate of all-cause death up to 1 year, in UA patients who have undergone PCI and have adequate LVEF. Its role in patients with AMI also deserves further exploration.
Keyphrases
- acute coronary syndrome
- end stage renal disease
- heart failure
- newly diagnosed
- chronic kidney disease
- acute myocardial infarction
- percutaneous coronary intervention
- coronary artery disease
- atrial fibrillation
- mesenchymal stem cells
- bone marrow
- angiotensin converting enzyme
- angiotensin ii
- coronary artery bypass grafting
- st elevation myocardial infarction
- st segment elevation myocardial infarction